Science

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

Francesco Soria/loop.frontiersin.org

Jan 22, 2025, 15:28

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

European Urology Oncology shared an article by Francesco Soria on X:

“Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group by Francesco Soria, et al.”

Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.

Authors: Francesco Soria, et al.

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

bladder cancer cancer Clinical validation European Urology Oncology fight against cancer Francesco Soria Global fight against cancer International Bladder Cancer Group NMIBC Non-muscle-invasive Bladder Cancer OncoDaily Oncology

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer